Manufacturing, Expression Systems

MilliporeSigma Launches Lentiviral Production Platform for Cell and Gene Therapies

October 16, 2020

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

October 02, 2020

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

iBio and Planet Biotechnology Partner to Develop COVID-19 Therapeutic

September 02, 2020

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

August 28, 2020

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

MilliporeSigma Adds Viral Vector and Gene Therapy Capacity

April 21, 2020

The company will build an additional commercial-scale, contract manufacturing facility for viral vectors and gene therapies near its existing site in Carlsbad, CA.

Absolute Antibody Launches New, High-Throughput Recombinant Antibody Production Service

March 05, 2020

The technology enables the rapid production of large numbers of recombinant antibodies at 80-mL scale.

Flexible Facilities for Viral Vector Manufacturing

March 02, 2020

Single-use and modular systems will meet demand for rapid implementation at different scales.

Dyadic Achieves G2 Human-Like Glycosylation Milestone

February 27, 2020

The company presented data on its G2 glycosylation studies at the 15th European Conference on Fungal Genetics in Rome on Feb. 19, 2020.

GE Healthcare Launches Viral Vector-Based Gene Therapy Manufacturing

October 28, 2019

GE Healthcare Life Sciences’ KUBio box is an integrated, flexible biomanufacturing environment for viral vector-based gene therapies.

Turning to Plant Cell Culture for Sustainability

September 01, 2019

In an effort to secure a continuous, sustainable supply of an important vaccine ingredient, Agenus is turning to a plant cell-based cell culture method for production.